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CD8+ cytotoxic T lymphocytes (CTLs) kill neoplastic cells
through the recognition of short peptide epitopes (8–12 amino
acids long) presented by major histocompatibility complex (MHC)
class I molecules that are expressed on the target cell surface
(Kronenberg et al, 1986; Henkart, 1994). Although the recognition
of peptide-MHC class I complexes is sufficient to trigger tumour
cell lysis, priming of CTL responses requires the presentation of the
relevant antigen by professional antigen-presenting cells (APCs)
capable of providing co-stimulation. Vaccines and immunotherapies
that preferentially prime this component of the immune response are
critical for establishing effective host tumour immunity. 
Dendritic cells (DCs) are professional APCs playing a key func-
tion in the immune system as initiators of T-cell responses against
microbial pathogens and tumours (Steinman, 1991; Banchereau
and Steinman, 1998). Immature DCs capture and process antigens
in peripheral tissues and begin to mature. The mature DCs migrate
to lymphoid organs, where they stimulate naïve T cells through the
signals of both MHC molecules presenting antigen-peptides and
costimulatory molecules (Austyn et al, 1988; Rock, 1996).
Therefore, immunization using DCs loaded with tumour-associated
antigens (TAAs) is potentially a powerful method of inducing 
anti-tumour immunity. In fact, a number of studies have shown
that immunization of mice by DCs pulsed with TAAs can prime a
tumour-specific CTL response and engender protective tumour
immunity (Mayordomo et al, 1995; Celluzzi et al, 1996; Nair et al,
1997). These results provide a promising experimental basis for
developing clinical trials of the anti-tumour therapy using DCs
(Hsu et al, 1996; Nestle et al, 1998; Lodge et al, 2000). However,
further investigation of DC-based immunotherapy is required to:
(1) establish efficient methods for collection and expansion of
large numbers of DC precursors (Romani et al, 1994; Bernhard 
et al, 1995); (2) improve methods for induction and purification of
effective DCs (Fearnley et al, 1997; Brossart et al, 1998; Lutz et al,
1999; Muller et al, 2000); (3) identify and select antigens (e.g.
peptides, proteins, DNA, mRNA, or tumour lysate) that can elicit
specific and effective immune responses (Ashley et al, 1997;
Nestle et al, 1998; Philip et al, 2000); (4) develop methods for effi-
cient introduction of antigens into DCs (Nair et al, 1992; Arthur et
al, 1997; Gong et al, 1997; Tillman et al, 1999); (5) identify an opti-
mized DC-immunization protocol (Eggert et al, 1999; Fallarino et
al, 1999; Lappin et al, 1999); and (6) confirm the safety of a DC-
vaccination (Roskrow et al, 1999; Ludewig et al, 2000). 
In the present research, we examined the usefulness of Lipo-
fectin™, a commercially available cationic liposome for intro-
ducing plasmid DNA, for the introduction of exogenous
antigens into DCs by evaluating antigen presentation on MHC
class I molecules. In order to identify the DC-immunization
protocol that exhibits the most superior anti-tumour effect, we
investigated the vaccine efficiency of DC2.4 cells, a murine
dendritic cell line, pulsed with ovalbumin (OVA) after i.v., i.p.,
i.d., or s.c. immunization in the murine E.G7-OVA tumour model. In
addition, we investigated the effect of OVA-pulsed DC2.4 cells-
immunization route on the induction of OVA-specific CTL response
and on the migration of DC2.4 cells to regional lymph nodes.
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Summary Dendritic cells (DCs) loaded with tumour antigens have been successfully used to induce protective tumour immunity in murine
models and human trials. However, it is still unclear which DC administration route elicits a superior therapeutic effect. Herein, we investigated
the vaccine efficiency of DC2.4 cells, a murine dendritic cell line, pulsed with ovalbumin (OVA) in the murine E.G7-OVA tumour model after
immunization via various routes. After a single vaccination using 1 ´ 106 OVA-pulsed DC2.4 cells, tumour was completely rejected in the
intradermally (i.d.; three of four mice), subcutaneously (s.c.; three of four mice), and intraperitoneally (i.p.; one of four mice) immunized
groups. Double vaccinations enhanced the anti-tumour effect in all groups except the intravenous (i.v.) group, which failed to achieve
complete rejection. The anti-tumour efficacy of each immunization route was correlated with the OVA-specific cytotoxic T lymphocyte (CTL)
activity evaluated on day 7 post-vaccination. Furthermore, the accumulation of DC2.4 cells in the regional lymph nodes was detected only in
the i.d.-and s.c.-injected groups. These results demonstrate that the administration route of antigen-loaded DCs affects the migration of DCs
to lymphoid tissues and the magnitude of antigen-specific CTL response. Furthermore, the immunization route affects vaccine efficiency. ©
2001 Cancer Research Campagin http://www.bjcancer.com
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MATERIALS AND METHO0DS 
Cells and animals 
DC2.4 cells (H-2b) and RF33.70 cells (T-T hybridoma against
OVA+ H-2Kb) were generously provided by Dr K L Rock
(Department of Pathology, University of Massachusetts Medical
School, MA, USA). DC2.4 cells, a DC line established from bone
marrow cells of C57BL/6 mice by infection with a retrovirus
encoding v-myc and  v-raf (Shen et al, 1997), were grown in
complete RPMI 1640 medium (10% fetal bovine serum, 2 mM L-
glutamine, 100 mg/ml streptomycin, and 100 U/ml penicillin)
supplemented with non-essential amino acid (100 mM) and 2-
mercaptoethanol (2-ME: 50 mM). RF33.70 cells (Rock et al, 1990;
Shen et al, 1997) were maintained in complete RPMI 1640 medium
supplemented with 50 mM 2-ME. CTLL-2 cells, which proliferate
specifically in response to interleukin-2 (IL-2) (Harding, 1994),
were maintained in complete RPMI 1640 medium supplemented
with 50 mM 2-ME and 10 U/ml murine recombinant IL-2 (Pepro
Tech EC LTD., London, England). E.G7-OVA tumour cells (H-2b;
OVA-transfectant of EL4 murine thymoma cells) were maintained
in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 50 mM 2-ME and 400 mg/ml G418. EL4 cells and YAC-1
cells, which are highly sensitive to natural killer cells (Cikes et al,
1973), were maintained in complete RPMI 1640 medium supple-
mented with 50 mM 2-ME. 
Female C57BL/6 mice, aged 7–8 weeks, were purchased from
SLC Inc. (Hamamatsu, Japan) and held under specified pathogen-
free conditions. All of the experimental procedures carried out were
in accordance with the Kyoto Pharmaceutical University guidelines
on animal experiments and the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR) guidelines for the
welfare of animals in experimental neoplasia. 
Antigen presentation assay 
DC2.4 cells were seeded in a 96-well flat-bottom culture
plate at a density of 1 ´ 104 cells/well and cultured overnight.
Lipofectin™ (Life Technologies, Tokyo, Japan), composed of N-
[1-(2,3-dioleyloxy)propyl]-N, N, N-trimethylammonium chloride
(DOTMA) and dioleoyl phosphatidylethanol amine (DOPE),
was mixed at a final concentration of 10 mg/ml with various
concentrations of OVA (Sigma Chemical Co., St Louis, MO,
USA) in Opti-MEM (Life Technologies), and incubated for 20
min at room temperature. Each well was washed twice with Opti-
MEM, and then the cells were incubated with various concentra-
tions of soluble OVA or OVA-Lipofectin complex in 100 ml of
Opti-MEM. After 5-h incubation at 37˚C, each well was washed
twice and incubated in the absence or presence of mitomycin C
(MMC: 50 mg/ml in Opti-MEM) at 37˚C for 30 min. After washing
with Opti-MEM, OVA-pulsed DC2.4 cells were co-cultured with
specific T-T hybridoma against OVA+ H-2Kb, RF33.70 cells (Rock
et al, 1990; Shen et al, 1997). The response of stimulated RF33.70
cells (1 ´ 105 cells/well) was assessed by determining IL-2 released
into an aliquot of complete RPMI 1640 medium (200 ml) at 37˚C.
Briefly, the culture medium was collected after 20-h co-culturing of
OVA-pulsed DC2.4 cells and RF33.70 cells. Serially diluted culture
medium was added to the CTLL-2 cells seeded on 96-well flat-
bottom culture plates at a density of 5 ´ 103 cells/well. Two days
later, the number of viable CTLL-2 cells was evaluated by MTT
assay (Mosmann, 1983). The concentration of IL-2 released from
RF33.70 cells was calculated from a standard curve obtained
from the MTT activity of CTLL-2 cells cultured in the presence
of various concentrations of murine recombinant IL-2. 
Loading OVA into DC2.4 cells using lipofectin 
Lipofectin was mixed at a final concentration of 10 mg/ml with
OVA at a final concentration of 1 mg/ml in Opti-MEM, and incu-
bated for 20 min at room temperature. The OVA-Lipofectin mixture
was added to a DC2.4 cell pellet (1 ´ 106 cells/ml) that was previ-
ously washed twice in Opti-MEM, and the final solution incubated
at 37˚C in a water bath with occasional agitation for 5 h. After
washing with phosphate-buffered saline (PBS), the cells were
treated with MMC (50 mg/ml in Opti-MEM) at 37˚C for 30 min in
order to inhibit proliferation. OVA-pulsed DC2.4 cells were then
washed twice and resuspended with PBS prior to immunization. 
Tumour rejection assay 
C57BL/6 mice were immunized once or twice over a 1-week interval
with OVA-pulsed DC2.4 cells. Cells (1 ´ 106 cells/100 ml/mouse)
were injected into the lateral tail vein (i.v.), peritoneum (i.p.), or
right flank (i.d. or s.c.). One week after the final vaccination, 1 ´
106 E.G7-OVA tumour cells were inoculated into the left flank.
Tumour size was assessed three times a week using microcalipers
and was expressed as tumour volume, calculated by the following
formula (Janik et al, 1975): tumour volume (mm3) = (major axis) ´
(minor axis)2 ´ 0.5236. Mice with tumour sizes > 2.5 cm or
tumour volume > 2500 mm3 were euthanized. On day 60 after
tumour challenge, all survivors were euthanized. 
Europium-release assay for detecting OVA-specific
CTLs 
C57BL/6 mice were immunized once with OVA-pulsed or non-
pulsed DC2.4 cells (1 ´ 106 cells). At one week after immunization,
spleens were excised and single cells suspensions were prepared.
The splenocytes were re-stimulated in vitro with E.G7-OVA cells
pre-treated with MMC (50 mg/ml in Opti-MEM) at 37˚C for 30 min,
at an effector:stimulator ratio of 10:1 in complete RPMI 1640
medium. Five days after re-stimulation, europium (Eu)-labeling of
target cells (E.G7-OVA cells, EL4 cells, and YAC-1 cells) and
Eu-release assay were performed according to the methods of
Volgmann et al (1989). In brief, target cells (5–10 ´ 106) were
labeled with Eu chelate (Eu-diethylenetriamine pentaacetate) for
20 min at 4˚C. Eu-labeled targets (1 ´ 104 cells) were incubated with
serially diluted effector cells at various effector:target (E:T) ratios in
100 ml of complete RPMI 1640 medium on 96-well U-bottomed
culture plates. The plates were centrifuged at 500 ´ g for 3 min and
incubated at 37˚C for 4 h. The addition of 150 ml of an enhancement
solution (Amersham Pharmacia Biotech, Tokyo, Japan) containing
b-naphthoyltrifluoroacetone to 50 ml of culture supernatant aliquots
leads to the formation of a highly fluorescent Eu-chelate that can be
measured with a time-resolved fluorometer (Ex: 340 nm, Em: 612
nm; SPECTARAFLUOR Plus, TECAN, Tokyo, Japan). Specific
cytotoxic activity was determined using the following formula:
specific lysis (%) = [(experimental Eu-release – spontaneous Eu-
release) / (maximum Eu-release – spontaneous Eu-release)] ´ 100.
Spontaneous Eu-release of the target cells was < 10% of maximum
Eu-release by detergent in all assays. SEM was less than 5% of
triplicate cultures. 1566 N Okada et al 
British Journal of Cancer (2001) 84(11), 1564–1570 © 2001 Cancer Research Campaign
Estimation of DC2.4 cells migration to the lymphoid
tissues by polymerase chain reaction (PCR) 
C57BL/6 mice were injected with 1 ´ 107 OVA-pulsed DC2.4 cells
via various routes including i.v. (lateral tail vein), i.p., i.d. (right
flank), and s.c. (right flank). At 48 h after injection, mice were
sacrificed and thymus, spleen, Peyer’s patches and lymph nodes
(cervical, brachial, axillary, mesenterial, renal, lumbal, pygal, in-
guinal, and ischial) were excised and genomic DNA was isolated
from these tissues. Because v-myc is inserted in genomic DNA of
DC2.4 cells (Shen et al, 1997), we attempted to estimate the migra-
tion of DC2.4 cells to the lymphoid tissues by amplification of the
v-myc gene using PCR. The primers for v-myc amplification were
designed based on GeneBank data for v-myc derived from avian
myelocytomatosis virus (accession No. V01173) and had the
following sequence: forward, 5¢-AACGAGTCTGAATCCAGC
AC-3¢; reverse, 5¢-TGCAAGACAGAGAGGTTAGC-3¢. Genomic
DNA isolated from DC2.4 cells was used as a positive control. The
amplification conditions were as follows: after denaturation at
94˚C for 2 min, denaturation at 94˚C for 45 s, annealing at 52˚C for
45 s, and extension at 72˚C for 45 s were repeated for 35 cycles
and followed by completion at 72˚C for 4 min. The size of the
expected PCR product was 414 bp. The PCR product was sepa-
rated on 3% agarose gel, stained with ethidium bromide, and visu-
alized under ultraviolet radiation. EZ Load™ (BIO-RAD, Tokyo,
Japan) was used as a molecular ruler. 
RESULTS 
DC2.4 cells pulsed with OVA-Lipofectin efficiently
present OVA-peptides on MHC class I molecules 
In the present study, we used DC2.4 cells, a murine dendritic cell
line (Shen et al, 1997), as APCs. Immunofluorescence analysis
and flow cytometry confirmed the expression of MHC class I and
II molecules and costimulatory molecules such as B7-1 (CD80),
B7-2 (CD86), and CD40 on the surface of DC2.4 cells (data not
shown). To investigate antigen presentation of OVA-pulsed DC2.4
cells via MHC class I molecules, we performed an antigen presen-
tation assay by measuring the production of IL-2 from RF33.70
cells specific for OVA peptides bound to MHC class I molecules
(Rock et al, 1990; Shen et al, 1997) (Figure 1). No significant
change in IL-2 levels was observed in the co-cultures of soluble
OVA-pulsed DC2.4 cells and RF33.70 cells, even when 10 mg/ml
of soluble OVA was pulsed onto DC2.4 cells. On the other hand,
when pulsed with OVA-Lipofectin (10 mg/ml), DC2.4 cells effi-
ciently presented OVA-peptides on MHC class I molecules in an
OVA concentration-dependent manner. 
Because DC2.4 cells are an established cell line, the permanent
proliferation of DC2.4 cells must be inhibited for in vivo vaccina-
tion. Therefore, we examined the effect of 50 mg/ml of MMC on
the MHC class I presentation of DC2.4 cells pulsed with OVA-
Lipofectin complexes. MMC-treatment did not affect the presenta-
tion of OVA-peptides via MHC class I molecules on DC2.4 cells
(Figure 1). In addition, we confirmed that the MMC-treated DC2.4
cells maintained their viability without cell growth for at least 5
days in vitro, and did not show tumour formation when injected
i.d. at 5 ´ 106 cells per mouse (data not shown). Taken collectively,
these results suggest that MMC-treated DC2.4 cells pulsed with
OVA-Lipofectin complexes may be useful for vaccination in sub-
sequent experiments. 
Protective effect against challenge with E.G7-OVA
tumour cells varies with vaccination route 
We next determined the effects of administration routes of antigen-
loaded DCs on the efficacy of DC-based immunotherapy. As
shown in Figure 2, C57BL/6 mice were immunized once with 
1 ´ 106 OVA-pulsed DC2.4 cells by i.v., i.p., i.d., or s.c. injection.
After inoculation with E.G7-OVA tumour cells on day 7 post-
vaccination, the anti-tumour efficacy was found to vary based on
the injection site of OVA-pulsed DC2.4 cells, although delay in
tumour growth was observed in all immunized groups. No tumour
formation was observed in the i.d.-and s.c.-injected groups or in
three of four mice in the i.p.-injected group on day 21 post-tumour
challenge. However, tumour formation was observed in all mice
immunized by i.v. administration. Moreover, three of four mice in
the i.d.-and s.c.-injected groups achieved complete rejection by day
60 after E.G7-OVA tumour challenge (Table 1). This anti-tumour
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Figure 1 Antigen presentation on MHC class I molecules by DC2.4 cells
pulsed with soluble OVA or OVA-Lipofectin complexes. DC2.4 cells were
incubated for 5 h at 37˚C with indicated concentrations of OVA in soluble
form (l l) or in complex with 10 mg/ml Lipofectin (l, n). After washing, the
cells were incubated in the presence (n) or the absence (l l, l) of 50 mg/ml 
of MMC at 37˚C for 30 min. Antigen presentation was determined by the
CTLL-2 bioassay described in Materials and Methods. Each point represents
the mean±SD of three independent cultures
Table 1 Summary of anti-E.G7-OVA tumour effects after immunization with
OVA-pulsed DC2.4 cells
Immunization
Tumour volumea (mm3) Complete rejectionb
Schedule Route 
i.v. 69.8 615.8 1028.7 2092.4 0/4 
i.p. 0.0 0.0 0.0 877.4 2/4 
Once i.d. 0.0 0.0 0.0 0.0 3/4 
s.c. 0.0 0.0 0.0 0.0 3/4 
i.v. 0.0 0.0 978.7 1276.3 0/4 
i.p. 0.0 0.0 0.0 0.0 4/4 
Twice i.d. 0.0 0.0 0.0 0.0 4/4 
s.c. 0.0 0.0 0.0 0.0 4/4 
1341.6 1873.2 >2500 >2500 0/4 
aDay 21 after tumour challenge. Tumour volume (mm3) = (major axis) ´
(minor axis)2 ´ 0.5236. bDay 60 after tumour challenge, tumour-rejected mice/
tumour-inoculated mice. Vaccine efficiency of DCs administered via various routes 1567
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effect of OVA-pulsed DC2.4 cells was OVA-specific because after
inoculation with EL4 tumour cells, parent cells of E.G7-OVA
tumour growth was not affected by vaccination with OVA-pulsed
DC2.4 cells (data not shown). Two vaccinations over a 1-week
interval further potentiated the anti-tumour effect of all OVA-
pulsed DC2.4 cell administration routes (Table 1). Complete
protection against E.G7-OVA tumour challenge was achieved in
all mice immunized twice with 1 ´ 106 OVA-pulsed DC2.4 cells
via i.p., i.d., or s.c. route. Repeating the i.v. immunization failed 
to achieve complete rejection, although two of four mice were
tumour-free on day 21 post-tumour challenge. These results
demonstrated that the vaccine efficiency of DCs pulsed with anti-
gens was obviously influenced by the administration route and the
immunization schedule. 
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Figure 2 Influence of administration route of OVA-pulsed DC2.4 cells on vaccine efficiency against E.G7-OVA tumour growth. C57BL/6 mice were immunized
once via various routes by 1 ´ 106 DC2.4 cells pulsed with OVA (1 mg/ml)-Lipofectin. One week later, 1 ´ 106 E.G7-OVA tumour cells (OVA-transfectant of EL4
mouse thymoma cells) were intradermally inoculated into the left flank. The size of growing E.G7-OVA tumours was measured every 2–3 days using
microcalipers. Each group consisted of four mice. †: Two mice were euthanized because tumour volumes were in excess of 2500 mm3. Administration routes of OVA-pulsed DC2.4 cells affect
OVA-specific CTL response 
Antigen-pulsed DC vaccines have been reported to trigger a specific
CTL response directly (Paglia et al, 1996; Alters et al, 1998; Wong
et al, 1998). We therefore used the Eu-release assay to determine the
influence of OVA-pulsed DC2.4 cell administration route on the
induction of the OVA-specific CTL response. Spleen cells were pre-
pared from mice on day 7 after vaccination with OVA-pulsed DC2.4
cells via various routes. Cytotoxic effectors were generated by co-
culturing spleen cells for 5 days with E.G7-OVA cells treated with
MMC. As shown in Figure 3, strong lytic activity against E.G7-
OVA cells was elicited in cultured spleen cells from mice adminis-
tered OVA-pulsed DC2.4 cells i.d. or s.c. In contrast, moderate and
low killing of E.G7-OVA cells was observed in the i.p.-and i.v.-
immunized groups, respectively. Cytotoxic activity against EL4
cells and YAC-1 cells, which are highly sensitive to natural killer
cells (Cikes et al, 1973), failed to be generated by vaccination with
OVA-pulsed DC2.4 cells. This observation strongly suggested that
the lysis of E.G7-OVA cells was due to the OVA-specific CTL
activity. Collectively, these results demonstrate that the induction of
antigen-specific CTL response is greatly affected by the administra-
tion route of the antigen-loaded DCs. 
Assessment of OVA-pulsed DC2.4 cell migration to
lymphoid tissues 
After activation by antigen challenge, DCs mature and migrate to
the secondary lymphoid tissues in which they present the pro-
cessed antigen to naïve T cells (Austyn et al, 1988; Rock, 1996).
Thus, we investigated the migration of OVA-pulsed DC2.4 cells to
the lymphoid organs in response to various administration routes.
Since the DC2.4 cell line was reported to be established by infec-
tion with a retrovirus encoding v-myc and v-raf (Shen et al, 1997),
we determined that the presence of DC2.4 cells in lymphoid
tissues after vaccination could be detected by PCR using primer
pairs specific for v-myc. Genomic DNA isolated from various
lymphoid organs was subjected to PCR and the products were
analyzed. In the case of i.d. administration of DC2.4 cells, DNA
isolated from lumbal, pygal, inguinal, and ischial lymph nodes
produced a PCR product of expected size (414 bp) (Figure 4, third
panel). In the case of s.c. administration, the specific PCR product
was amplified from lumbal, inguinal, and ischial lymph nodes
(Figure 4, fourth panel). In contrast, genomic DNA from various
lymphoid tissues failed to generate this PCR product after i.v. and
i.p. administration of DC2.4 cells (Figure 4, first and second
panels). These data show that i.d.-and s.c.-administered DC2.4
cells preferentially migrate to the regional lymph nodes, where
DC2.4 cells interact with naïve T cells to prime an antigen-specific
immune response. Therefore, the differential migration of OVA-
pulsed DC2.4 cells following their administration by the i.v., i.p.,
i.d., or s.c. routes is reflected in their potency to induce OVA-
specific CTL responses. 
DISCUSSION 
DCs are professional APCs capable of capturing antigens and
processing and presenting antigenic peptide fragments. Mature
DCs can migrate to lymphoid organs to prime T cell immune
responses (Austyn et al, 1988; Rock, 1996; Banchereau and
Steinman, 1998). Due to these properties, DCs are considered
promising tools for cancer immunotherapy. For successful DC-
based immunotherapies, antigens must be efficiently introduced
into DCs and presented on MHC class I molecules at high levels,
to activate CD8+ CTLs. We have been exploring methods for
loading exogenous antigens into APCs showing high MHC class I
presentation efficiency (Hayashi et al, 1999; Nakanishi et al,
2000). In the present study, we tested the cationic liposome, Lipo-
fectin, for loading an exogenous antigen, OVA, into the murine
DC2.4 cell line, which has been reported to possess morphological
and functional properties of DCs (Shen et al, 1997). DC2.4 cells
pulsed with OVA-Lipofectin complexes showed more efficient
presentation of OVA-peptides on MHC class I molecules than
soluble OVA-pulsed DC2.4 cells (Figure 1). In most cells, antigens
in the extracellular fluids do not ordinarily access the MHC class I
pathway for antigen presentation. In contrast, DCs have been
reported to transfer the exogenous antigens from the endocytic
compartment into the cytosol, where they are degraded and
presented via the classical MHC class I pathway. This process is
markedly enhanced when the antigens are internalized by phago-
1568 N Okada et al 
British Journal of Cancer (2001) 84(11), 1564–1570 © 2001 Cancer Research Campaign
0
10
20
30
40
50
60
25 50 75
ET ratio
100
S
p
e
c
i
f
i
c
 
l
y
s
i
s
 
(
%
)
Target: E.G7-OVA cells
0
10
20
30
40
50
60
25 50 75
ET ratio
100
S
p
e
c
i
f
i
c
 
l
y
s
i
s
 
(
%
)
Target: EL4 cells
0
10
20
30
40
50
60
25 50 75
ET ratio
100
S
p
e
c
i
f
i
c
 
l
y
s
i
s
 
(
%
)
Target: YAC-1 cells
Figure 3 OVA-specific CTL responses in mice immunized with OVA-pulsed DC2.4 cells via various routes. C57BL/6 mice were immunized by i.v. (n), i.p. (∆ ),
i.d. (l), and s.c. (n n) injection with 1 ´106 OVA-pulsed DC2.4 cells. Similarly, non-pulsed DC2.4 cells (O) were injected into mice intradermally. One week later,
mice were sacrificed, their spleens removed and splenocytes were prepared. After in vitro restimulation with E.G7-OVA cells for 5 days, effector cells were
incubated with Eu-labeled target cells (E.G7-OVA cells, EL4 cells, or YAC-1 cells) at 37˚C for 4 h. The specific lysis of target cells was determined by using the
following formula; Specific lysis (%)=[(experimental Eu-release)-(spontaneous Eu-release)]/[(maximum Eu-release)-(spontaneous Eu-release)] ´ 100.
Spontaneous release in the absence of effector cells was <10% of maximum release by detergent. All data points represent the average of two independent
experiments, which were performed with 3–5 mice per groupVaccine efficiency of DCs administered via various routes 1569
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cytosis (Shen et al, 1997), macropinocytosis (Norbury et al, 1997),
or receptor-mediated endocytosis (Rodriguez et al, 1999; Machy et
al, 2000). In some cases, peptides derived from the exogenous
antigens appear to be generated in the endocytic compartments
and then bind to MHC class I molecules on the cell surface
(Zitvogel et al, 1998). Although the pathway of internalized OVA-
Lipofectin complexes in DC2.4 cells remains to be elucidated, we
speculate that the transfer of OVA to the MHC class I pathway
may be greatly facilitated by Lipofectin because DC2.4 cells used
phagocytosis not pinocytosis to capture exogenous OVA associ-
ated with Lipofectin. Elucidation of intracellular trafficking of
antigens loaded with Lipofectin and of the transport mechanism of
the antigen-Lipofectin complex in DCs is important for estab-
lishing methods for efficient introduction of antigens into DCs
showing high MHC class I presentation efficiency. 
Several studies have shown that ex vivo-differentiated DCs 
may enable specific vaccination for generating protective tumour
immunity in human clinical trials (Hsu et al, 1996; Nestle et al,
1998; Lodge et al, 2000). However, it is still unclear which 
DC administration route elicits superior therapeutic effects in 
DC-based immunotherapy. In order to elucidate this issue, we per-
formed E.G7-OVA tumour rejection assays in mice immunized via
various administration routes with DC2.4 cells pulsed with OVA-
Lipofectin complexes. Although tumour growth was delayed in all
groups, the ratio of complete rejection on day 60 after tumour
challenge differed with the administration route of OVA-pulsed
DC2.4 cells (Table 1). Moreover, the anti-tumour effect was
enhanced in all groups by a twice repeated vaccination with OVA-
pulsed DC2.4 cells. These results suggest that the route of admin-
istration and the immunization schedule of OVA-pulsed DC2.4
cells affect the induction of OVA-specific host immunity. In addi-
tion, these results are confirmed by the OVA-specific CTL
response after vaccination with OVA-pulsed DC2.4 cells via
various routes. High cytotoxicity due to OVA-specific CTLs was
shown in splenocytes isolated from mice injected i.d. and s.c. with
OVA-pulsed DC2.4 cells, whereas moderate and low CTL
response was observed in i.p. and i.v. administered mice, respec-
tively (Figure 3). The magnitude of OVA-specific CTL response
induced by immunizing with OVA-pulsed DC2.4 cells, positively
correlated with the results of the E.G7-OVA tumour rejection
assay for each vaccination route. 
The migration of antigen-loaded DCs to secondary lymphoid
tissues is essential for efficient induction of the antigen-specific
CTL response. Lappin et al (1999) reported that DCs were found
in popliteal lymph nodes at 24 h following their s.c. injection into
footpads. The number of DCs peaked at 48 h and decreased to
background levels by day 5 after injection (Lappin et al, 1999).
Based on their report, we investigated by PCR the migration of
OVA-pulsed DC2.4 cells to the lymphoid tissues, 48 h after injec-
tion. The PCR product for v-myc was successfully amplified from
genomic DNA isolated from the regional lymph nodes of i.d.-or
s.c.-injected mice, while no PCR products were found in any
lymphoid tissues of i.v.-or i.p.-injected mice (Figure 4). These
results clearly indicate that the DC2.4 cells administered i.d. or s.c.
preferentially migrated to the regional lymph nodes as compared
with i.v.-and i.p.-injected DC2.4 cells. Therefore, we reasoned that
the various anti-E.G7-OVA tumour effects of OVA-pulsed DC2.4
cells reflected the extent of their migration to the regional lymph
nodes and thereby the induction of OVA-specific CTL response. 
Recent advances in biological and immunological research on
DCs have introduced the potential use of specific antigen-loaded
DCs as nature’s adjuvant against cancer. DC-based immun-
otherapy is expected to show strong anti-tumour effects against
microscopic metastases that are otherwise incurable. However,
further studies are required to improve the effectiveness of DC-
based immunotherapy. In the present report, we provided evidence
that the administration route affected the migration of antigen-
loaded DCs to the regional lymph nodes and thereby dominated
host tumour immunity based on the antigen-specific CTL
response. These results demonstrate that the route of administra-
tion of DCs should be considered as an important variable when
designing vaccination protocols using DCs loaded with antigens. 
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